FDA Issues Final Order Permanently Debarring Individual for Felony Related to Drug Product Development

What this means for your practice

This FDA debarment notice serves as a critical reminder for all healthcare businesses, including telehealth brands, medspas, dental practices, and chiropractic offices, about the importance of rigorous due diligence in hiring and contracting. While this specific case involves drug product development, the underlying principle of avoiding individuals debarred by federal agencies is broadly applicable. Businesses that deal with prescription medications, medical devices, or even offer services ancillary to such products, must ensure that no personnel, contractors, or affiliates are on any federal debarment lists. Employing or contracting with a debarred individual can lead to significant regulatory penalties, reputational damage, and even exclusion from federal healthcare programs. Regularly checking federal databases, such as those maintained by the FDA and HHS-OIG, is a best practice to mitigate compliance risks and ensure adherence to federal regulations like the Federal Food, Drug, and Cosmetic Act.

Rockville, MD — The Food and Drug Administration (FDA) has announced a final debarment order against Ricardo Andres Acuna, permanently prohibiting him from providing services to any person or entity that possesses an approved or pending drug product application. This significant regulatory action underscores the FDA's commitment to maintaining the integrity of the drug development and approval process.

Basis for Debarment

The FDA's decision to debar Mr. Acuna is based on a specific provision within the Federal Food, Drug, and Cosmetic Act (FD&C Act). Section 306(a)(2)(A) of the FD&C Act mandates the debarment of an individual if the FDA finds that they were convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product.

In this instance, the Agency found that Mr. Acuna met these criteria. The specific nature of the felony conviction was determined to be directly related to the critical processes surrounding drug product development or approval.

Procedural History

Following the determination of his felony conviction, Mr. Acuna was duly notified of the proposed debarment by the FDA. This notice included an explicit opportunity for him to request a hearing to present his case within a timeframe prescribed by regulation. However, as of May 6, 2026, which was 30 days after his receipt of the notice, Mr. Acuna failed to submit a response. According to regulatory procedures, this lack of response constitutes a waiver of his right to a hearing concerning the matter of his debarment.

Consequently, the FDA proceeded to issue this final debarment order, effective August 3, 2026, making the prohibition permanent.

Implications of a Permanent Debarment

A permanent debarment, as issued by the FDA, means that Ricardo Andres Acuna is prohibited from providing services in *any capacity* to an entity involved with approved or pending drug product applications. This broad prohibition aims to safeguard public health and maintain the trustworthiness of the pharmaceutical industry by preventing individuals who have committed serious offenses related to drug integrity from influencing or participating in drug-related activities.

Possibility of Special Termination

The FD&C Act does provide a pathway for individuals subject to debarment to apply for special termination. Under section 306(d)(4) of the FD&C Act (21 U.S.C. 335a(d)(4)), Mr. Acuna may submit an application for special termination at any time. The process for submitting such an application is detailed, offering both electronic and written/paper submission options.

Electronic Submissions: Applications can be submitted via the Federal eRulemaking Portal at www.regulations.gov. Applicants are advised to follow the instructions carefully and be aware that electronic submissions, including attachments, will be publicly posted unchanged. Therefore, sensitive or confidential information should be redacted or submitted via the written/paper method.

Written/Paper Submissions: These can be mailed or hand-delivered to the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For confidential information, specific instructions must be followed: two copies should be submitted, one marked “THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION” and a second redacted copy for public viewing. Any information identified as confidential will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law.

All applications, regardless of submission method, must include the Docket No. FDA-2026-N-1535. The FDA Dockets Management Staff is available for public viewing of received applications between 9 a.m. and 4 p.m., Monday through Friday.

This debarment serves as a strong signal from the FDA regarding the severe consequences of felony convictions related to the drug product lifecycle and emphasizes the regulatory body's ongoing efforts to protect the integrity of the drug supply chain.

Key Facts

| Detail | Value | |---|---| | Debarred Individual | Ricardo Andres Acuna | | Action Taken | Permanent Debarment from providing services to persons with approved or pending drug product applications | | Basis for Debarment | Conviction of a felony under Federal law for conduct relating to the development or approval of any drug product (FD&C Act section 306(a)(2)(A)) | | Effective Date | August 3, 2026 | | Docket Number | FDA-2026-N-1535 | | Waiver of Hearing | Mr. Acuna failed to respond within 30 days of receiving notice, waiving his right to a hearing |

Frequently Asked Questions

What does it mean to be 'debarred' by the FDA?

To be debarred by the FDA means an individual is permanently prohibited from providing services in any capacity to a person or company that has an approved or pending drug product application.

Why was Ricardo Andres Acuna debarred?

Ricardo Andres Acuna was debarred because he was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product.

Can a debarred individual ever work in the drug industry again?

A debarred individual may apply for 'special termination of debarment' under section 306(d)(4) of the FD&C Act. The FDA provides a process for submitting such an application.

What happens if a debarred individual doesn't respond to the FDA's notice?

If a debarred individual does not respond and request a hearing within the prescribed timeframe after receiving notice, it constitutes a waiver of their right to a hearing, and the debarment order becomes final.

How can I submit an application for special termination of debarment?

Applications for special termination can be submitted electronically via the Federal eRulemaking Portal at www.regulations.gov or as a written/paper submission mailed to the FDA's Dockets Management Staff. All applications must include Docket No. FDA-2026-N-1535.

Source: FDA — Notice: Ricardo Andres Acuna: Final Debarment Order · 2026-08-03